This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS
Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction.
Published: 3rd July 2019
Authors: W. H. Allum, E. C. Smyth, J. M. Blazeby, H. I. Grabsch, S. M. Griffin, S. Rowley et al.
Background
The UK Medical Research Council ST03 trial compared perioperative epirubicin, cisplatin and capecitabine (ECX) chemotherapy with or without bevacizumab (B) in gastric and oesophagogastric junctional cancer. No difference in survival was noted between the arms of the trial. The present study reviewed the standards and performance of surgery in the context of the protocol‐specified surgical criteria.
Method
Surgical and pathological clinical report forms were reviewed to determine adherence to the surgical protocols, perioperative morbidity and mortality, and final histopathological stage for all patients treated in the study.
Results
Of 1063 patients randomized, 895 (84·2 per cent) underwent resection; surgical details were available for 880 (98·3 per cent). Postoperative assessment data were available for 873 patients; complications occurred in 458 (52·5 per cent) overall, of whom 71 (8·1 per cent) developed complications deemed to be life‐threatening by the responsible clinician. The most common complications were respiratory (211 patients, 24·2 per cent). The anastomotic leak rate was 118 of 873 (13·5 per cent) overall; among those who underwent oesophagogastrectomy, the rate was higher in the group receiving ECX‐B (23·6 per cent versus 9·9 per cent in the ECX group). Pathological assessment data were available for 845 patients. At least 15 nodes were removed in 82·5 per cent of resections and the median lymph node harvest was 24 (i.q.r. 17–34). Twenty‐five or more nodes were removed in 49·0 per cent of patients. Histopathologically, the R1 rate was 24·9 per cent (208 of 834 patients). An R1 resection was more common for proximal tumours.
Conclusion
In the ST03 trial, the performance of surgery met the protocol‐stipulated criteria. Registration number: NCT00450203 (
You may also be interested in
Randomized clinical trial
Authors: K. Misawa, Y. Mochizuki, M. Sakai, H. Teramoto, D. Morimoto, H. Nakayama et al.
Randomized clinical trial
Authors: R. J. Hopkins, T. Irvine, G. G. Jamieson, P. G. Devitt, D. I. Watson
Randomized clinical trial
Authors: B. Sunde, F. Klevebro, A. Johar, G. Johnsen, A.‐B. Jacobsen, N. I. Glenjen et al.
Original article
Authors: Y. Baba, T. Yagi, K. Kosumi, K. Okadome, D. Nomoto, K. Eto et al.
Original article
Authors: Å. A. Fretland, V. J. Dagenborg, G. M. Waaler Bjørnelv, D. L. Aghayan, A. M. Kazaryan, L. Barkhatov et al.
Original article
Authors: J. A. Elliott, L. O'Byrne, G. Foley, C. F. Murphy, S. L. Doyle, S. King et al.
Systematic review
Authors: N. Moody, A. Adiamah, F. Yanni, D. Gomez
Article
Authors: Y. Y. Broza, S. Khatib, A. Gharra, A. Krilaviciute, H. Amal, I. Polaka et al.
Original article
Authors: S. Ahlin, C. Cefalù, I. Bondia‐Pons, E. Capristo, L. Marini, A. Gastaldelli et al.
Original article
Authors: A.‐H. Chen, W.‐H. Chan, Y.‐H. Lee, J.‐H. Tseng, T.‐S. Yeh, C.‐T. Chiu et al.
Original article
Authors: J. X. Lin, C. Yoon, J. Desiderio, B. C. Yi, P. Li, C. H. Zheng et al.
Original article
Authors: N. Takemura, T. Aoki, K. Hasegawa, J. Kaneko, J. Arita, N. Akamatsu et al.